Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

642.25 -9.55 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades'
Cisco reported fourth-quarter revenue of $14.67 billion, and there was a bout of profit taking, Cerity Partners' Jim Lebenthal says. 
Via Benzinga
REGENERON PHARMACEUTICALS (NASDAQ:REGN): A Prime Value Investing Candidate with Strong Fundamentals
Discover REGN, a top value investing stock. It boasts strong fundamentals, low P/E ratios, high profitability, and solid financial health, trading below its intrinsic worth. 
Via Chartmill
Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon
Via Stocktwits
Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions
Via Stocktwits
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
 
Via Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Top S&P500 movers in Monday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles
Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective corrective actions. 
Via Benzinga
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
These companies aren't performing as badly as their stock-market performances this year suggest. 
Via The Motley Fool
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday. 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Incyte (NASDAQ:INCY) and its peers. 
Via StockStory
Topics Artificial Intelligence
These S&P500 stocks are moving in today's session
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP profit of $12.89 per share was... 
Via StockStory
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point
Truist, however, kept a ‘Buy’ rating on the shares. 
Via Stocktwits
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings
 
Via Benzinga
How Do Investors Really Feel About Regeneron Pharmaceuticals?
 
Via Benzinga
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
 
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Regeneron Pharmaceuticals Stock
 
Via Benzinga
Is Regeneron Pharmaceuticals Gaining or Losing Market Support?
 
Via Benzinga
2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts
These biotech businesses look compelling for very different reasons. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.